The biotechnology sector is undergoing a transformation, driven by the integration of artificial intelligence (AI) and innovations in personalized therapies. However, it faces significant structural challenges, notably the "patent cliff," which threatens to reduce industry revenues by $400 billion. This massive patent expiration forces companies to innovate rapidly to offset the loss of revenue. The convergence of AI and biotechnology offers unprecedented opportunities but also raises ethical and security concerns, particularly regarding intellectual property and cyber risks.